Mucopolysaccharidosis I (MPS I) Registry
Mucopolysaccharidosis I (MPS I) Registry
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.
The objectives of the Registry are:
The MPS I Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact:
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90027, United States
Los Angeles, California 90033, United States
Oakland, California 94609, United States
Palo Alto, California 94305, United States
San Diego, California 92093, United States
San Francisco, California, United States
Washington D.C., District of Columbia 20010, United States
Gainesville, Florida 32610, United States
Decatur, Georgia 30033, United States
Chicago, Illinois 60611, United States
Indianapolis, Indiana 46202, United States
Boston, Massachusetts 02114, United States
Minneapolis, Minnesota 55455, United States
Hackensack, New Jersey 07601, United States
New Brunswick, New Jersey 08901, United States
Durham, North Carolina 27710, United States
Portland, Oregon 97239, United States
Philadelphia, Pennsylvania 19104, United States
Greenville, South Carolina 29605, United States
Charlottesville, Virginia 22908, United States
Norfolk, Virginia 23507, United States
Seattle, Washington 98195, United States
Milwaukee, Wisconsin 53226, United States
Porto Alegre, Rio Grande do Sul 90035-002, Brazil
Campinas, São Paulo 13034-685, Brazil
São Paulo, 04020-041, Brazil
Jeonnam, South Korea